The cross-sectional study was carried out between April 14 and May 13, 2020 and included all HCW who came from different hospital services and belonged to all professional categories (administrative and auxiliary services staff, central services technicians, cleaning staff, clinic assistants, doctors, nurses and watchmen). All HCW were invited to participate, recruited from hospital Human Resources database (as of April 10, 2020) by the Occupational Health Service (OHS) and summoned by the Admission Service coordinated with the hospital's Laboratory Medicine to perform the tests. A nasopharyngeal swab and venous blood sample were obtained simultaneously from all participants for molecular and serological diagnosis of SARS-CoV-2 infection, respectively. Both samples were sent during the next hour after collection and processed at the Medicine Laboratory. Nasopharyngeal samples were collected with flocked swabs in a viral transport medium that contains guanidine salts to inactivate and preserve the virus (Mole Bioscience, Taizhou, China). Nucleic acid extraction was performed in the QIAsymphony SP instrument with the QIAsymphony DSP Virus/Pathogen Midi Kit (Qiagen, Hylden, Germany) from 400 μl of sample or manually using the High Pure RNA Isolation Kit (Roche Diagnostics GmbH, Mannheim, Germany) from 200 μl of sample. Molecular detection was carried out by rRT-PCR in a LightCycler 480 System (Roche Diagnostics GmbH, Mannheim, Germany) using the LightMix® Modular SARS-CoV (COVID19) kit (Roche Diagnostics GmbH, Mannheim, Germany). Positive and negative controls as well as an internal control (LightMix® Modular EAV RNA Extraction Control) were included in each run. Serum IgG and IgM antibody directed against SARS-CoV-S (spike) and SARS-CoV-N (nucleocapside) recombinant antigens were measured in the Maglumi 2000 platform (Snibe diagnostic, Shenzhen, China) with the Maglumi 2019-nCoV (SARS-CoV-2) IgM and IgG kits in a fully automated chemiluminescence immunoassay (CLIA). The results were expressed in AU/mL and considered positive or negative following manufacturer's instructions. Once the rRT-PCR and the immunological study were analysed, a COVID status assessment report was prepared for each HCW, in which the clinical situation and symptom onset dates (if any) were assessed together with the test results carried out. A HCW was classified as asymptomatic if genetic material from SARS-COV-2 and/or serum IgG anti SARS-CoV-2 was detected but did not consult at the OHS due to compatible symptoms with COVID-19 infection [11].

The incidence study was carried out from the appearance of the first confirmed COVID-19 case in the hospital March 2, 2020 until May 13, and included those HCW who consulted at the OHS for confirmed exposure and/or presenting symptoms suggestive of COVID19 [11], as registered in the OHS database. For molecular detection of SARS-CoV-2 infection, at least one nasopharyngeal swab was obtained in viral transport medium and processed as stated previously. All these symptomatic workers were also included in the cross-sectional study as participants.

The following variables were collected from the participants in both studies: age, gender, assigned service, professional category and symptom onset dates (if any), as registered in the OHS and Human Resources Service database and HCW medical records.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.